Pulmatrix Inc
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic appli… Read more
Pulmatrix Inc (PULM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.218x
Based on the latest financial reports, Pulmatrix Inc (PULM) has a cash flow conversion efficiency ratio of -0.218x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.03 Million) by net assets ($4.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pulmatrix Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Pulmatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pulmatrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmatrix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kawasan Industri Jababeka Tbk
JK:KIJA
|
0.062x |
|
VOLT RESOURCES LTD
F:R8L
|
N/A |
|
Generic Engineering Construction and Projects Limited
NSE:GENCON
|
0.018x |
|
Vien Dong Investment Development Trading Corp
VN:VID
|
N/A |
|
Shindo Eng. Lab. Ltd
KQ:290520
|
-0.114x |
|
WCF Bancorp Inc
PINK:WCFB
|
0.005x |
|
SOLIDWORLD GROUP S.P.A.
F:F17
|
N/A |
|
Castile Resources Limited
PINK:CLRSF
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Pulmatrix Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Pulmatrix Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.95 Million | $-10.72 Million | -1.198x | -34.83% |
| 2023-12-31 | $18.00 Million | $-15.98 Million | -0.888x | -42.77% |
| 2022-12-31 | $31.11 Million | $-19.36 Million | -0.622x | -49.66% |
| 2021-12-31 | $47.45 Million | $-19.73 Million | -0.416x | +22.93% |
| 2020-12-31 | $23.14 Million | $-12.48 Million | -0.539x | -284.04% |
| 2019-12-31 | $11.02 Million | $3.23 Million | 0.293x | +120.71% |
| 2018-12-31 | $11.84 Million | $-16.76 Million | -1.415x | +0.91% |
| 2017-12-31 | $10.14 Million | $-14.48 Million | -1.428x | +5.52% |
| 2016-12-31 | $8.76 Million | $-13.24 Million | -1.512x | -295.18% |
| 2015-12-31 | $32.61 Million | $-12.47 Million | -0.383x | -88.47% |
| 2014-12-31 | $14.63 Million | $-2.97 Million | -0.203x | 0.00% |
| 2013-12-31 | $14.63 Million | $-2.97 Million | -0.203x | +97.76% |
| 2012-12-31 | $47.00K | $-426.00K | -9.064x | -- |